Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

A phase II study of Oxaliplatin Reintroduction in patients pretreated with Oxaliplatin and Irinotecan for Advanced Colorectal Cancer

ABSTRACT: Interventions: mFOLFOX6 5FU bolus: 400 mg/m2 d1 5FU infusion: 2400 mg/m2/46h d1 Oxaliplatin: 85mg/m2 d1 l-LV: 200mg/m2 d1 Q2w Primary outcome(s): Disease control rate after 12 weeks of treatment. Study Design: Single arm Non-randomized

DISEASE(S): Metastatic Colorectal Cancer

PROVIDER: 2620327 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR

ACCESS DATA

Json Xml

Similar Datasets

A phase II study of Perioperative FOLFOX4 plus Bevacizumab for initially unresectable Advanced Colorectal Cancer.

Project description:Interventions: FOLFOX4+Bevacizumab 5FU bolus: 400 mg/m2 d1,2 5FU infusion: 600 mg/m2/22h d1,2 Oxaliplatin: 85mg/m2 d1 l-LV: 100mg/m2 d1,2 bevacizumab: 5mg/kg d1 Bevacizumab 5mg/m2 d1 Q2w Primary outcome(s): Completion rate of neoadjuvant chemotherapy. Possibility of curative surgery. Study Design: Single arm Non-randomized

| 2621009 | ecrin-mdr-crc

Early tumor shrinkage of Cetuximab and mFOLFOX6 in RAS-wild type unresectable metastatic colorectal cancer.

Project description:Interventions: Weekly Cetuximab+mFOLFOX6 Cetuximab 400mg/m2/ initial 250mg/m2/ qw Oxaliplatin 85mg/m2/ qw l-LV 200mg/m2/ qw 5FU-bols 400mg/m2/ qw 5FU-infusional 2,400mg/m2/ qw OR Biweekly Cetuximab+mFOLFOX6 Cetuximab 500mg/m2/ q2w Oxaliplatin 85mg/m2/ q2w l-LV 200mg/m2/ q2w 5FU-bols 400mg/m2/ q2w 5FU-infusional 2,400mg/m2/ q2w Primary outcome(s): ETS(Early Tumor Shrinkage) rate Study Design: Single arm Non-randomized

| 2630670 | ecrin-mdr-crc

Response Rate of Bevacizumab and FOLFOXIRI with pegfilgrastim in RAS-mutant type unresectable metastatic colorectal cancer.

Project description:Interventions: Biweekly FOLFOXIRI+Bevacizumab +Pegfilgrastim Bevacizumab 5mg/kg/ q2w Oxaliplatin 85mg/m2/ q2w Irinotecan 165mg/m2/ q2w l-LV 200mg/m2/ q2w 5FU-infusional 3,200mg/m2/ q2w Pegfilgrastim 3.6mg / q2w Primary outcome(s): ORR: overall response rate Study Design: Single arm Non-randomized

| 2633492 | ecrin-mdr-crc

Feasibility study of Pre-operative FOLFIRI3 plus cetuximab for KRAS wild type resectable advanced colorectal cancer (mCRC).

Project description:Interventions: Pre-operative chemotherapy(FOLFIRI3 plusCetuximab)4cycles =>To evaluate effect =>Surgical resection or Continued chemotherapy =>Surgical resection. *FOLFIRI3 plus Cetuximab Cetuximab500 mg/m2/day1/q2w CPT-11 100 mg/m2/day1,3/q2w I-LV 200 mg/m2/day1/q2w 5-FU/infusional 2400 mg/m2/46hr/q2w Primary outcome(s): Treatment completion rate Study Design: Single arm Non-randomized

| 2625026 | ecrin-mdr-crc

Oligonucleotide Array CGH Profiles of Breast Cancer Patients Treated with High Dose or Conventional Chemotherapy

Project description:DNA copy number profiles can identify patients with a defect in BRCA1 or BRCA2. We previously showed that patients with a BRCA1 like profile benefit from intensified alkylating chemotherapy (IA, 4 cycles 5-fluorouracyl (5FU), epirubicin, cyclophosphamide (C) + 1 cycle carboplatin, thiotepa and cyclophosphamide with autologous stem cell transplantation (ASCT)). Presumably, this is because of the defect in error free homologous recombination DNA repair. Here we present an independent study IA chemotherapy (2 cycles induction, followed by ifosfamide, 12 g/m2; carboplatin, 900 mg/m2; and epirubicin, 180 mg/m2 with ASCT) versus anthracyclin-C (AC) or C-methothrexate-5FU (CMF) regimens in high risk breast cancer.

2014-12-22 | GSE50407 | GEO

An Exploratory Study for the Efficacy and Safety of Cetuximab in Combination with Irinotecan Re-challenge Versus Regorafenib in the Third-Line Treatment of RAS Wild-Type Metastatic Colorectal Cancer

Project description:Interventions: Experimental group:Cetuximab-targeted combination with irinotecan chemotherapy, the specific regimen is as follows: Cetuximab (trade name: Erbitux) once every two weeks, 500 mg/m2, d1; Irinotecan 180 mg/m2 ivgtt 90 min d1 q2w;Control group:Regorafenib oral treatment, the specific regimen is as follows: regorafenib 120 mg d1-21 q4w Primary outcome(s): Progression-free survival Study Design: Parallel

| 2687922 | ecrin-mdr-crc

Oligonucleotide Array CGH Profiles of Breast Cancer Patients Treated with High Dose or Conventional Chemotherapy

2014-12-22 | E-GEOD-50407 | biostudies-arrayexpress

Single-arm phase II exploratory study of cetuximab combined with camrelizumab in RAS wild-type recurrent or distantly metastatic advanced colorectal cancer after failure of second-line standard therapy

Project description:Interventions: Experimental group:Cetuximab:500mg/m2,d1,q2w Camrelizumab:200mg, d1, q2w Primary outcome(s): Objective response rate Study Design: Single arm

| 85219 | ecrin-mdr-crc

Nordic 8 - A Phase II Trial

Project description:Nordic randomized phase II trial which evaluates whether biweekly cetuximab with alternating FOLFIRI and mFOLFOX6 is more effective than biweekly cetuximab with continuously FOLFIRI in patients with potential resectable KRAS wildtype metastatic colorectal cancer. All patients will be randomized to biweekly cetuximab 500 mg/m2 in combination with arm A) FOLFIRI (irinotecan 180 mg/m2 IV, leucovorin: 400 mg/m2 IV, 5FU bolus: 400 mg/m2 IV and 46 hours 5FU infusion of 2400 mg/m2 every 2 weeks) or arm B) FOLFIRI alternating with FOLFOX6 (Oxaliplatin: 85 mg/m2 IV, leucovorin: 400 mg/m2 IV, 5FU bolus: 400 mg/m2 IV and 46 hours 5FU infusion of 2400 mg/m2 every 2 weeks) . Primary objective: response rate (RECIST 1.1) in patients with with potential resectable KRAS wildtype metastatic colorectal cancer. Secondary objectives: Resection rate, PFS, OS, Quality of life, tolerability. Biomarker evaluation to measure plasma biomarkers, Tumour blocks and sequential serum and plasma will be collected to search for markers that may predict efficacy including respectability and safety.

| 2145885 | ecrin-mdr-crc

A Phase II Study of Neoadjuvant Gemcitabine Plus Doxorubicin Followed by Gemcitabine Plus Cisplatin in Breast Cancer

Project description:This phase II study examined the pathological complete response (pCR) rate and safety of two gemcitabine-based combinations administered sequentially in breast cancer. We also examined gene expression profiles from tumor biopsies to identify biomarkers predictive of response. Methods: Indian women with large or locally advanced breast cancer received 4 cycles of gemcitabine 1200 mg/m2 plus doxorubicin 60 mg/m2 (Gem+Dox), then 4 cycles of gemcitabine 1000 mg/m2 plus cisplatin 70 mg/m2 (Gem+Cis), and surgery. To examine dynamic changes in molecular profiles after one dose of therapy, we used three alternate sequences during cycle 1 (Gem d1, 8; Dox d2; Gem d1, 8; Dox d1; or Gem d2, 8; Dox d1). Results: Of 65 women (median age 46) treated, 13 (24.5% of 53 patients with surgery) had a pCR and 22 (33.8%) had a complete clinical response. Patients who received Gem d1, 8 and Dox d2 in cycle 1 (20/65) reported more toxicities, with G3/4 neutropenic infection/febrile neutropenia (7/20) and vomiting (5/20) as the most common cycle 1 events. Four drug-related deaths occurred. 46/65 patients yielded successful pretreatment gene expression profiles. Ten-fold cross-validated supervised analyses identified gene expression patterns that predicted with >73% accuracy (1) clinical complete response after eight cycles, (2) overall clinical complete response, and (3) pCR. Conclusions: This neoadjuvant regimen showed strong activity. A subset of patients receiving Gem d1, 8 and Dox d2 experienced unacceptable toxicity, whereas patients on other sequences had more manageable safety profiles. The predictive gene expression patterns may provide a method for selecting patients most likely to benefit from gemcitabine-containing neoadjuvant therapy. Key words: breast cancer, chemotherapy, gemcitabine, , gene expression, microarrays, neoadjuvant therapy Keywords: Dose response

2008-01-12 | GSE8465 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data